KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Payables: 2009-2024

Historic Payables for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $19.1 million.

  • Pacira BioSciences' Payables fell 8.67% to $17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.1 million, marking a year-over-year increase of 43.55%. This contributed to the annual value of $19.1 million for FY2024, which is 21.88% up from last year.
  • Pacira BioSciences' Payables amounted to $19.1 million in FY2024, which was up 21.88% from $15.7 million recorded in FY2023.
  • Over the past 5 years, Pacira BioSciences' Payables peaked at $19.1 million during FY2024, and registered a low of $10.4 million during FY2020.
  • In the last 3 years, Pacira BioSciences' Payables had a median value of $15.7 million in 2023 and averaged $16.7 million.
  • As far as peak fluctuations go, Pacira BioSciences' Payables dropped by 18.50% in 2020, and later surged by 44.36% in 2022.
  • Pacira BioSciences' Payables (Yearly) stood at $10.4 million in 2020, then grew by 1.07% to $10.5 million in 2021, then spiked by 44.36% to $15.2 million in 2022, then increased by 3.14% to $15.7 million in 2023, then climbed by 21.88% to $19.1 million in 2024.